Phase 2 N=40 Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: Response Rate — .125 proportion of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=25 Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA
Stage IV Pancreatic Cancer
Primary: Complete Response Rate — 2; 15; 4; 3 Participants
N/A N=14 4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation
Pancreatic Adenocarcinoma
Primary: Individually Optimized Contrast-enhanced 4DCT for Radiotherapy Simulation — 4.1; 2.5; 3.6; 3.9 units on a scale
Phase 2 N=54 Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma
Locally Advanced Pancreatic Adenocarcinoma
Primary: Number of Subjects With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 4; 23 Participants
Phase 2 N=48 Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
Pancreatic Cancer · Pancreatic Adenocarcinoma · Pancreas Ductal Adenocarcinoma
Primary: R0 Resection Rates in Each Cohort as Measured by Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins — 9; 9 participants with resectable PDAC
Phase 3 N=861 Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
Metastatic Pancreatic Cancer
Primary: Overall Survival (OS) — 8.5; 6.7 months — p=<0.0001
Phase 2 N=63 Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma
PDAC - Pancreatic Ductal Adenocarcinoma · FAP
Primary: Sensitivity of [68Ga]FAPI-46 PET Imaging to Detect PDAC, Using Histopathology as Truth Standard — 0.741 proportion of participants
Phase 2 N=16 Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)
Pancreatic Cancer · Pancreatic Ductal Adenocarcinoma · Pancreatic Adenocarcinoma
Primary: Best Overall Response (BOR) — 0; 0; 3; 11 Participants
Phase 2 N=229 Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Pancreatic Adenocarcinoma
Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants
Phase 2 N=42 Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
Primary: 12- Month Overall Survival (OS) — 16 Participants
Phase 3 N=866 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
Pancreatic Neoplasms · Digestive System Neoplasms · Neoplasms by Site
Primary: Kaplan Meier Estimate for Disease Free Survival (DFS) According to the Independent Radiological Review Committee — 19.4; 18.8 months — p=0.1824
Phase 2 N=23 Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma
Metastatic Pancreatic Ductal Adenocarcinoma
Primary: Number of Participants With Dose-Limiting Toxicities (DLT) — 0; 4 Participants
N/A N=105 Pancreatic Juice Diagnosis From Duodenum
Pancreatic Adenocarcinoma
Primary: The Concentration of the Pancreatic Cancer Markers of the Normal Cohort and UICC Stage II Pancreatic Ductal Adenocarcinoma Cohort — 99097; 34095 pg/ml — p=<0.001
Phase 3 N=211 Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma
Metastatic Pancreatic Adenocarcinoma
Primary: Overall Survival — 6.4; 5.9 months
Phase 2 N=9 Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer
Pancreatic Neoplasms
Primary: Maximal Tolerated Dose (MTD) & Dose Limiting Toxicity (DLT) of Intratumoral Injections of BC-819 — 0; 1 participants
Phase 2 N=23 PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer
Metastatic Pancreatic Cancer
Primary: Progression-Free Survival (PFS) — 6.05; 5.26 months — p=0.058
Phase 1 N=76 Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC
Metastatic Pancreatic Ductal Adenocarcinoma
Primary: Number of Participants With Dose Limiting Toxicities — 0; 1; 0; 0 Participants
Phase 2 N=72 Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
Metastatic Pancreatic Cancer
Primary: Progression Free Survival With the Combination of GDC-0449 With Gemcitabine and Nab-paclitaxel. — 5.42 months
Phase 2 N=77 ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer
Metastatic Pancreatic Cancer
Primary: Number of Participants With Overall Response Advanced or Metastatic Pancreatic Cancer. — 0; 3 Participants
Phase 2 N=106 A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
Primary: Stage 1: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD)…
Phase 2 N=204 Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma
Pancreatic Cancer
Primary: Hazard of Progression in the Placebo/Placebo Arm and the Pooled Demcizumab Arms — 38; 70; 5; 12 Participants — p==0.7158
Phase 2 N=107 Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)
Pancreatic Neoplasms
Primary: Kaplan-Meier Estimates for Time to Treatment Failure (TTF) — 9.0 months
Phase 2 N=180 Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma
Primary: Overall Survival — 8.8; 9.8 months — p=0.72
Phase 2 N=35 Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: Local Progression-free Survival (LPFS) — 22.30801 months
Phase 2 N=48 ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)
Pancreatic Cancer
Primary: Recurrence Free Survival — 15.6 months
N/A N=30 Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer
Pancreatic Cancer
Primary: Deoxyhemoglobin Concentration (DHb) — .6968475; .3483283; .7021826; .4945491 alpha units — p=0.001
Phase 2 N=60 Vaccine Therapy Combined With Adjuvant Chemoradiotherapy in Treating Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas
Pancreatic Cancer
Primary: Overall Survival — 24.8 Months
Phase 2 N=39 Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Percentage of Participants Without Disease Progression (Progression-Free Survival) at 6 Months — 78.6; 30 percentage of participants
Phase 2 N=67 Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer
Metastatic Pancreatic Cancer
Primary: Number of Participants With Dose-limiting Toxicities — 4; 0; 1 participants
Phase 2 N=37 TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer
Pancreatic Cancer
Primary: Number of Patients With Treatment Related Serious Adverse Events — 0; 1; 0 Participants